Triple Negative Breast Neoplasms

Oncology·MeSH: Triple Negative Breast Neoplasms

Prevalence

287.0 / 100K

Incidence

128.0 / 100K/yr

4 drugs in development·2 companies·13 clinical trials

Drug Pipeline by Phase

Compare drugs

350 mg leronlimab vs 525 mg leronlimab350 mg leronlimab vs 700 mg leronlimab350 mg leronlimab vs Oleclumab

Frequently asked questions

How many drugs are in development for Triple Negative Breast Neoplasms?

BioSniper tracks 4 drugs in development for Triple Negative Breast Neoplasms across 2 companies.

How many clinical trials target Triple Negative Breast Neoplasms?

There are 13 clinical trials targeting Triple Negative Breast Neoplasms tracked by BioSniper.

What is the prevalence of Triple Negative Breast Neoplasms?

The estimated prevalence of Triple Negative Breast Neoplasms is approximately 287.0 per 100,000 population.

Deep-dive into Triple Negative Breast Neoplasms

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Triple Negative Breast Neoplasms — Drugs in Development & Clinical Trials | BioSniper